Background/Objectives Atrial fibrillation/flutter (AF) and liver cirrhosis both present a large disease burden internationally, with millions of adults afflicted. There is evidence of a link between these two diseases; however, the prevalence and impact of liver cirrhosis in patients with and without AF have not been extensively detailed. With the utilization of a large national database, we examined the relationship between liver cirrhosis and AF and the effects on hospital outcomes. Methods We conducted a nationwide review from 2016 to 2020 utilizing the Nationwide Inpatient Sample (NIS) database. Patients ≥ 18 years old with newly diagnosed atrial fibrillation or atrial flutter were identified. They were then further stratified into patients with and without liver cirrhosis. Characteristics and comorbidities were identified, evaluating in-hospital mortality as the primary outcome. Results A total of 3,866,486 patients with a primary diagnosis of AF were included. Patients with liver cirrhosis were younger in age (mean age 68.32 vs 74.36 years old), the majority were White (74.1%), followed by Black (10.2%), and Hispanic (10.5%). They had more comorbidities, such as diabetes (45.1% vs 37.3%, p<0.001), hypertension (78.5% vs 83.6%, p<0.01), and chronic kidney disease (22.1% vs 19.5%, p<0.001) when compared to patients without liver cirrhosis. Patients with liver cirrhosis had a higher risk of in-hospital mortality (OR=1.84, p<0.001), hypovolemic shock (OR=2.17, p<0.001), gastrointestinal bleed (OR=2.42, p<0.001), requiring blood transfusions (OR=1.84, p<0.001), and requiring ICU-level of care with intubation (OR=1.214, p<0.001), central line (OR=1.33, p<0.001), arterial line (OR=1.32, p<0.001) and vasopressors (OR=1.61, p<0.001). Moreover, patients with liver cirrhosis had a lower risk of having an acute cerebrovascular accident (OR=0.431), transient ischemic attack (OR=0.475), or pulmonary embolism (OR=0.68) while hospitalized (p<0.001). Conclusion Our results have demonstrated a remarkable relationship between AF and liver cirrhosis, with significantly increased morbidity and mortality reported in individuals with both conditions compared to AF without liver cirrhosis.

The recent redefinition of steatotic liver diseases, introducing metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), reflects a growing consensus among liver societies and marks a paradigm shift in disease classification. MASLD subsumes former categories of nonalcoholic fatty liver disease (NAFLD) and incorporates metabolic criteria alongside moderate alcohol intake, while MASH replaces nonalcoholic steatohepatitis (NASH), aligning terminology with disease mechanisms. This evolution clarifies the diagnostic criteria and minimizes stigma, facilitating more consistent epidemiological and clinical investigations. Recent advances in noninvasive diagnostics, including vibration-controlled transient elastography, magnetic resonance elastography, shear-wave elastography, and the Enhanced Liver Fibrosis test, have improved the identification and stratification of patients with advanced fibrosis. Current guidelines recommend targeted screening in populations at elevated metabolic risk, enabling earlier intervention and personalized management. Population studies indicate that MASLD affects over one-third of adults and is a major contributor to cardiovascular and metabolic morbidity. Therapeutic progress is highlighted by the approval of novel agents such as resmetirom and semaglutide for the treatment of MASH with fibrosis. Emerging dual and triple agonists, as well as sodium–glucose cotransporter inhibitors, offer additional promise, although further research is required to define their long-term efficacy and safety. As the disease prevalence escalates globally, the integration of multidisciplinary care, the ongoing refinement of diagnostic tools, and the expansion of therapeutic options will remain essential to optimizing outcomes for affected individuals.